U.S. District Court issues Restasis patents trial decision

Wednesday, October 18, 2017

Allergan, a global biopharmaceutical company, acknowledged that the U.S. District Court for the Eastern District of Texas has issued an adverse trial decision finding that the four asserted patents covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05% are invalid. The company will appeal the Court’s ruling.

[Read More]

TransCelerate BioPharma adds Novartis

Monday, September 18, 2017

TransCelerate BioPharma announces the addition of Novartis to the biopharmaceutical nonprofit organization, growing the consortium to 19 biopharmaceutical companies. In addition, TransCelerate membership have elected Elliott Levy, M.D., Senior Vice President, Global Development at Amgen as the new Chair of the Board of the Directors and David Nicholson, Ph.D., Executive Vice President, and Chief R&D Officer at Allergan, will assume the Vice Chair role.

[Read More]

iBIO Institute announces iCON Awards honorees

Tuesday, August 22, 2017

The iBIO Institute announced the four honorees of the eleventh annual iCON Awards—a prestigious honor for life sciences educators, researchers and civic visionaries. The iCON Awards celebrate the accomplishments of outstanding innovators and leaders whose work provides the basis for biotechnology developments worldwide.

[Read More]

GenSight Biologics appoints Mohamed Genead as chief medical officer

Thursday, May 4, 2017

GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announced it has appointed Mohamed Genead, M.D., as chief medical officer. Dr. Genead brings more than 15 years of experience to the role, including his most recent role as vice president & global therapeutic area head for Ophthalmology/Retina Gene Therapy at Biogen.

[Read More]

Allergan names Daphne Karydas SVP, Global Investor Relations & Strategy

Tuesday, April 11, 2017

Allergan, a global biopharmaceutical company, announced that Daphne Karydas will join the company as senior vice president of Global Investor Relations and Strategy, effective April 17, 2017. In this role, Karydas will lead the company’s engagement with the investment community, and will work with the company’s executive leadership team to develop and execute the company’s long-term business strategy. Karydas will report to Tessa Hilado, chief financial officer of Allergan.

[Read More]

Allergan, Editas Medicine partner on CRISPR genome editing medicines for eye diseases

Wednesday, March 15, 2017

Allergan, a global pharmaceutical company, and Editas Medicine, a genome editing company, have announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development alliance under which Allergan will receive exclusive access and the option to license up to five of Editas Medicine’s genome-editing ocular programs, including its lead program for Leber Congenital Amaurosis (LCA10), which is currently in preclinical development.

[Read More]

Novo Nordisk, Servier, Otsuka, Teva among top sponsors

Wednesday, March 1, 2017

Sponsors have done a good job of maintaining, but not improving, the overall quality of their relationships with investigative sites during the past two years, according to a new CenterWatch survey, but performance gaps have widened across several of the attributes sites identify as the most important for conducting a successful study.

[Read More]

A cautiously optimistic healthcare M&A outlook for 2017

Monday, February 13, 2017

Although 2016 was a lackluster year for megadeals in healthcare, a recent flurry of big deals has Wall Street investors cautiously optimistic that 2017 will bring new mergers and big-ticket acquisitions. An increasingly competitive landscape in healthcare, coupled with signs that the new U.S. presidential administration may usher in more business-friendly policies, could spur major deals in the upcoming year.

[Read More]